The global Antibiotic Resistance Market size is estimated to reach USD 12.07 billion by 2025. According to a new report by Grand View Research, Inc., it is anticipated to post a CAGR of 5.6% during the forecast period. Rising burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been driving the market.
Biotech
companies that are developing therapies for antibiotic-resistant infections
include Melinta Therapeutics, Achaogen, and Nabriva Therapeutics. On the other
hand, majority of large pharmaceutical companies don’t find this market
lucrative enough due to slower growth in revenues for marketed drugs and lower
return on investments. For instance, Novartis recently discontinued development
of its antibacterial drugs for antibiotic resistance.
Manufacturers
can obtain the Qualified Infectious Disease Product (QIDP) designation, which
escalates the clinical review process for antibacterial therapies targeting
high priority pathogens. The QIDP designation enables faster access to targeted
agents and was introduced under the GAIN (Generating Antibiotic Incentives Now)
Act, passed in 2012 as an extension to the U.S. FDA Safety and Innovation Act.
The legislation aims to encourage the development of novel therapies for
growing burden and severity of infections with antibiotic resistance.
Related Press Release@ Antibiotic Resistance Market Report
Antibiotic Resistance Market Report Highlights
- In 2017, the
market by cUTI disease registered significant sales due to elevated rate
of resistance in extended-spectrum beta-lactamase (ESBL)-producing and
carbapenem-resistant Enterobacteriaceae and P. aeruginosa strains
- The
combination therapies segment, which includes fixed-dose combinations of
beta lactams and beta lactamase inhibitors, is projected to witness the
fastest growth rate over the forecast period
- Infections
due to E. coli pathogens that are ESBL-producing and carbapenem-resistant
led in terms of sales revenue in 2017 due to high treatment cost
- On the
geographical front, North America was the dominant revenue contributor in
the market in 2017. Improving reimbursement scenario with new technology
add-on payment provision is promoting the use of novel products in this
region
- Among pharmaceutical
companies, Merck, Allergan, and
Pfizer were the key players with top-selling drugs in the antibiotic
resistance market in 2017.
List of Key
Players in Antibiotic Resistance Market
·
Achaogen, Inc.
·
Basilea Pharmaceutica Ltd.
·
Melinta Therapeutics
·
Tetraphase Pharmaceuticals, Inc.
·
Theravance Biopharma, Inc.
·
Wockhardt therapeutics
·
Entasis Therapeutics
·
PARATEK therapeutics
·
Seres Therapeutics, Inc.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment